ロード中...
Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses
Few cancer drugs or their indications achieved survival benefit in subsequent trials during postmarket period after approval based on surrogate endpoints. This causes a concern of using surrogate endpoints instead of overall survival (OS) as the primary endpoint for trial design, implementation and...
保存先:
| 出版年: | Ann Transl Med |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AME Publishing Company
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6603357/ https://ncbi.nlm.nih.gov/pubmed/31317014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.04.72 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|